Redeye retains its positive view of CombinedX following a solid Q3, showing increasing margins due to finalised integrations and acquisitions. As the driver behind the improvement should persist, we expect further improvements in R12m numbers, although we have revised our previously optimistic Q4 and Q1 assumptions somewhat downward.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/